Publications en collaboration avec des chercheurs de Hospital Ramón y Cajal (347)

2024

  1. Central American and Caribbean Consensus Document for the Optimal Management of Oral Anticoagulation in Patients with Non-Valvular Atrial Fibrillation Endorsed by the Central American and Caribbean Society of Arterial Hypertension and Cardiovascular Prevention

    Journal of Clinical Medicine, Vol. 13, Núm. 2

  2. Characteristics of women with type 2 diabetes mellitus and heart failure in Spain. The DIABET-IC study

    Cardiology Journal, Vol. 31, Núm. 1, pp. 103-110

  3. Clinical profile and outcomes in very elderly patients with atrial fibrillation anticoagulated with rivaroxaban: data from the EMIR study

    Journal of Geriatric Cardiology, Vol. 21, Núm. 7, pp. 723-732

  4. Impact of the presence and type of cardiovascular disease on the risk of mortality in type 2 diabetic patients: The DIABET-IC trial

    Endocrinologia, Diabetes y Nutricion, Vol. 71, Núm. 7, pp. 278-289

  5. New technologies for the diagnosis, treatment, and monitoring of cardiovascular diseases

    Revista Espanola de Cardiologia, Vol. 77, Núm. 1, pp. 88-96

  6. Post-event follow-up costs in patients with atherosclerotic cardiovascular disease in Spain

    Frontiers in Cardiovascular Medicine, Vol. 11

  7. Practical use of new therapies for the management of dyslipidaemias. Consensus SEC/SEA/SEEN/SEMFYC/SEMERGEN/SEMG/SEN/SEACV/S.E.N.

    REC: CardioClinics, Vol. 59, Núm. 4, pp. 310-321

  8. Prevalence and incidence of heart failure in type 2 diabetes patients: results from a nationwide prospective cohort—the DIABET-IC study

    Cardiovascular Diabetology, Vol. 23, Núm. 1

2023

  1. Association between sacubitril/valsartan initiation and changes in left ventricular ejection fraction: Insights from ARIADNE registry

    International Journal of Cardiology, Vol. 370, pp. 279-286

  2. Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity

    Clinical and Translational Oncology, Vol. 25, Núm. 11, pp. 3073-3085

  3. Cost-effectiveness of the CNIC-Polypill versus separate monocomponents in cardiovascular secondary prevention in Spain

    Revista Clinica Espanola, Vol. 223, Núm. 7, pp. 414-422

  4. Current situation of the comprehensive approach of heart failure in Spain. The OPTIMISE-IC project

    REC: CardioClinics, Vol. 58, Núm. 4, pp. 289-302

  5. Impact of Advanced Age on the Incidence of Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stable Coronary Artery Disease in a Real-World Setting in Spain

    Journal of Clinical Medicine, Vol. 12, Núm. 16

  6. Impact of COVID-19 pandemic on the sanitary assistance of atrial fibrillation in Spain

    REC: CardioClinics, Vol. 58, Núm. 3, pp. 241-244

  7. Impact of the Spanish consensus for improving lipid control on patients admitted for an acute coronary syndrome

    Journal of Clinical Lipidology, Vol. 17, Núm. 6, pp. 756-764

  8. Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban

    Journal of comparative effectiveness research, Vol. 12, Núm. 3, pp. e220049

  9. Prevalence Rates of Arterial Hypertension According to the Threshold Criteria of 140/90 or 130/80 mmHg and Associated Cardiometabolic and Renal Factors: SIMETAP-HTN Study

    Medicina (Lithuania), Vol. 59, Núm. 10

  10. Real-World Attainment of Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Cardiovascular Disease Treated with High-Intensity Statins: The TERESA Study

    Journal of Clinical Medicine, Vol. 12, Núm. 9

  11. SGLT 2 inhibitors: Searching for the best in class

    International Journal of Cardiology

  12. STRUGGLE FOR. Italian-Polish-Spanish-Uzbek--Vietnamese Expert Forum Position Paper 2023 for better control of classical modifiable risk factors in clinical practice

    Cardiology Journal, Vol. 30, Núm. 6, pp. 859-869